研究疾病:
|
流感
|
研究疾病代码:
|
|
Target disease:
|
Influenza
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
主要目的:
初步评价柴银颗粒治疗流行性感冒(外感风热证)的有效性;
次要目的:
1.初步评价柴银颗粒治疗流行性感冒(外感风热证)的安全性;
2.基于全社会角度,初步进行柴银颗粒治疗流行性感冒(外感风热证)的成本-效果分析,为临床应用与准入决策提供科学依据。
|
Objectives of Study:
|
Primary objective:
To evaluate the effectiveness of Chaiyin granules in the treatment of influenza(exogenous wind-heat syndrome);
Secondary objective:
1.To evaluate the safety of Chaiyin granules in the treatment of influenza(exogenous wind-heat syndrome);
2.From a social perspective,preliminary cost-effectiveness analysis of Chaiyin granules in the treatment of influenza(exogenous wind-heat syndrome),to provide scientific basis for clinical application and admittance decision.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
(1)年龄18-65岁,性别不限;
(2)符合流行性感冒的西医诊断标准;
(3)流感快速抗原检测结果为阳性者;
(4)符合中医外感风热证的辩证标准;
(5)腋温≥38℃者;
(6)发病48h内(发病起始时间定义:发热并伴有其他典型流感症状如头痛、肌痛、畏寒、寒战、肌肉关节酸痛、乏力、咽喉痛、干咳、鼻塞、流涕等至少出现 1 项);
(7)试验前签署知情同意书、并对试验内容、过程及可能出现的不良反应充分了解。
|
Inclusion criteria
|
(1)Aged 18 to 65 years old,no gender limitation;
(2)Consistent with the clinical diagnosis of influenza;
(3)Patients whose rapid influenza diagnostic tests result are positive;
(4)Patients who accord with the dialectical standard of exogenous wind-heat syndrome in traditional Chinese medicine;
(5)The axillary temperature 38 ℃ or higher;
(6)Course within 48 hours(Definition of onset time of disease:fever with other typical flu symptoms,for instance headache,myalgia,chilly,shiver,joint pain,weak,pharyngalgia,cough,nasal congestion,runny nose,etc.at least one of the above);
(7)Sign the informed consent before the test,and have a good understanding of the test contents, process and possible adverse reactions.
|
排除标准:
|
(1)过敏体质或对试验药物或对照药物已知成分过敏者;
(2)符合国家卫生部发布的《流行性感冒诊疗方案(2020年版)》的重症与危重症病例诊断标准者;
(3)出现其他需进行监护治疗的严重临床情况;
(4)急性细菌性鼻窦炎、过敏性鼻炎、气管炎-支气管炎、肺炎、疱疹性咽峡炎等疾病者;
(5)合并心脑血管、肺、肾和造血系统严重原发性疾病者;
(6)有急慢性肠胃炎及给药前1周内有不明原因腹泻者;
(7)肝功能检测值(ALT、AST)超过正常值上限的1.5倍;血肌酐超过正常值上限;
(8)血白细胞<3.0×109/L或>10.0×109/L;和/或中性粒细胞总数>正常值上限,考虑细菌感染者;
(9)给药前24小时内使用治疗本病的其他药物者(包括抗病毒、激素等中西药物和治疗方法);
(10)怀疑或确有酒精或药物滥用史;
(11)妊娠或准备妊娠妇女,哺乳期妇女,试验期间不能或不愿意采取充分避孕的育龄期或其配偶不愿意采取避孕措施者;
(12)有精神障碍等不能合作者;
(13)近3个月内参加过其他干预性临床试验者;
(14)研究者认为不适宜参加本临床试验者。
|
Exclusion criteria:
|
(1)Allergic constitution or allergic to known components of the test drug or control drug;
(2)Patients who accord with the diagnostic criteria of Severe and critically ill cases in Influenza Diagnosis and Treatment Protocol (2020 Edition) published by National Health Commission;
(3)The occurrence of other serious clinical conditions requiring monitoring treatment;
(4)Patients with acute bacterial sinusitis,anaphylactic rhinitis,tracheitis - bronchitis,pneumonia,herpangina,etc.;
(5)Patients with serious primary diseases of cardiovascular,cerebrovascular,lung,kidney and hematopoietic system;
(6)Patients with acute or chronic gastroenteritis and unexplained diarrhea 1 week before administration;
(7)Liver function test values (ALT, AST) were 1.5 times higher than the upper limit of normal values;Serum creatinine exceeds the upper limit of normal;
(8)Blood leukocyte <3.0×10^9/L or >10.0×10^9/L;and/or neutrophils above the upper limit of normal values,consider bacterial infection;
(9)Patients who have taken other medications for the disease within 24 hours prior to administration(Including antiviral, hormone and other Chinese and western drugs and treatment methods);
(10)Suspected or present history of alcohol or drug abuse;
(11)Pregnancy,preparing for pregnancy or lactating women,patients who are in reproductive age unable or unwilling take adequate contraceptive measures or their spouse's reluctance to use contraception;
(12)Patients with mental disorders who are unable to cooperate;
(13)Participated in other interventional clinical trials within the last 3 months;
(14)Patients deemed unsuitable by the investigator to participate in this clinical trial.
|
研究实施时间:
Study execute time:
|
从From
2021-01-04
至To
2023-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-04-13
至To
2023-04-30
|